BG62618B1 - Асиметрично заместени ксантини с аденозинантагонистичнисвойства, метод за тяхното получаване и междинни съединения затази цел, приложение на тези съединения като фармакологичнисредства, фармацевтични смеси, които ги съдържат, и метод затяхното получаване - Google Patents

Асиметрично заместени ксантини с аденозинантагонистичнисвойства, метод за тяхното получаване и междинни съединения затази цел, приложение на тези съединения като фармакологичнисредства, фармацевтични смеси, които ги съдържат, и метод затяхното получаване Download PDF

Info

Publication number
BG62618B1
BG62618B1 BG99489A BG9948995A BG62618B1 BG 62618 B1 BG62618 B1 BG 62618B1 BG 99489 A BG99489 A BG 99489A BG 9948995 A BG9948995 A BG 9948995A BG 62618 B1 BG62618 B1 BG 62618B1
Authority
BG
Bulgaria
Prior art keywords
och
conr
radical
substituted
general formula
Prior art date
Application number
BG99489A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG99489A (bg
Inventor
Ulrike Kuefner-Muehl
Helmut Ensinger
Joachim Mierau
Franz J. Kuhn
Erich Lehr
Enzio Mueller
Original Assignee
Boehringer Ingelheim Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Kg filed Critical Boehringer Ingelheim Kg
Publication of BG99489A publication Critical patent/BG99489A/bg
Publication of BG62618B1 publication Critical patent/BG62618B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Laser Surgery Devices (AREA)
  • Radiation-Therapy Devices (AREA)
  • Thermotherapy And Cooling Therapy Devices (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
BG99489A 1992-08-10 1995-03-09 Асиметрично заместени ксантини с аденозинантагонистичнисвойства, метод за тяхното получаване и междинни съединения затази цел, приложение на тези съединения като фармакологичнисредства, фармацевтични смеси, които ги съдържат, и метод затяхното получаване BG62618B1 (bg)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4226371 1992-08-10
DE4238423 1992-11-13
PCT/EP1993/002077 WO1994003456A1 (de) 1992-08-10 1993-08-05 Unsymmetrisch substituierte xanthine mit adenosinantagonistischen eigenschaften

Publications (2)

Publication Number Publication Date
BG99489A BG99489A (bg) 1996-01-31
BG62618B1 true BG62618B1 (bg) 2000-03-31

Family

ID=25917371

Family Applications (1)

Application Number Title Priority Date Filing Date
BG99489A BG62618B1 (bg) 1992-08-10 1995-03-09 Асиметрично заместени ксантини с аденозинантагонистичнисвойства, метод за тяхното получаване и междинни съединения затази цел, приложение на тези съединения като фармакологичнисредства, фармацевтични смеси, които ги съдържат, и метод затяхното получаване

Country Status (21)

Country Link
US (1) US5719279A (cs)
EP (1) EP0654033A1 (cs)
JP (1) JPH08500344A (cs)
KR (1) KR950702988A (cs)
CN (1) CN1043348C (cs)
AU (1) AU681348B2 (cs)
BG (1) BG62618B1 (cs)
CA (1) CA2140883A1 (cs)
CZ (1) CZ286459B6 (cs)
FI (1) FI950542A7 (cs)
HU (1) HUT65734A (cs)
IL (1) IL106624A (cs)
MX (1) MX9304819A (cs)
NZ (1) NZ254804A (cs)
PL (1) PL176389B1 (cs)
RU (1) RU2138500C1 (cs)
SG (1) SG55038A1 (cs)
SK (1) SK18595A3 (cs)
TW (1) TW252044B (cs)
UA (1) UA46697C2 (cs)
WO (1) WO1994003456A1 (cs)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW252044B (cs) * 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
US5877179A (en) * 1992-09-29 1999-03-02 The United States Of America As Represented By The Department Of Health And Human Services Xanthines for identifying CFTR--binding compounds useful for activating chloride conductance in animal cells
WO1994025462A1 (en) * 1993-05-03 1994-11-10 The United States Of America, Represented By The 8-substituted 1,3,7-trialkyl-xanthine derivatives as a2-selective adenosine receptor antagonists
DE4316576A1 (de) * 1993-05-18 1994-11-24 Boehringer Ingelheim Kg Verbessertes Verfahren zur Herstellung von 1,3-Dipropyl-8-(3-Oxocyclopentyl)-xanthin
US5646156A (en) * 1994-04-25 1997-07-08 Merck & Co., Inc. Inhibition of eosinophil activation through A3 adenosine receptor antagonism
US5591776A (en) 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
GB9415529D0 (en) 1994-08-01 1994-09-21 Wellcome Found Phenyl xanthine derivatives
AU4527996A (en) 1994-12-13 1996-07-03 Euro-Celtique S.A. Trisubstituted thioxanthines
EP0814809B1 (en) * 1994-12-13 2003-08-13 Euroceltique S.A. Aryl thioxanthines
US5864037A (en) * 1996-06-06 1999-01-26 Euro-Celtique, S.A. Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity
GB9623859D0 (en) * 1996-11-15 1997-01-08 Chiroscience Ltd Novel compounds
US5786360A (en) * 1996-11-19 1998-07-28 Link Technology Incorporated A1 adenosine receptor antagonists
GB9703044D0 (en) 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
US6248746B1 (en) 1998-01-07 2001-06-19 Euro-Celtique S.A. 3-(arylalkyl) xanthines
WO1999031101A1 (en) * 1997-12-17 1999-06-24 University Of South Florida Adenosine receptor antagonists with improved bioactivity
DE19816857A1 (de) * 1998-04-16 1999-10-21 Boehringer Ingelheim Pharma Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU4980999A (en) 1998-07-10 2000-02-01 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The A3 adenosine receptor antagonists
GB9817623D0 (en) 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
EP1230243B1 (en) * 1999-11-12 2009-03-04 Biogen Idec MA Inc. Poycyloalkylpurines as adenosine receptor antagonists
NZ519427A (en) 1999-11-12 2003-08-29 Biogen Inc Polycycloalkylpurine derivative useful as an adenosine receptor antagonist
EP1251130B1 (en) * 1999-12-24 2005-02-16 Kyowa Hakko Kogyo Co., Ltd. Fused purine derivatives
AU3091301A (en) 2000-01-14 2001-07-24 Us Health Methanocarba cycloalkyl nucleoside analogues
GB0008694D0 (en) * 2000-04-07 2000-05-31 Novartis Ag Organic compounds
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
MXPA03007349A (es) * 2001-02-24 2003-12-04 Boehringer Ingelheim Pharma Derivados de xantina, su preparacion y su empleo como medicamentos.
UA80258C2 (en) * 2001-09-06 2007-09-10 Biogen Inc Methods of treating pulmonary disease
US7125993B2 (en) * 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
WO2004009091A1 (en) 2002-06-17 2004-01-29 Glaxo Group Limited Purine derivatives as liver x receptor agonists
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7495005B2 (en) 2002-08-22 2009-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
US7569574B2 (en) 2002-08-22 2009-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7482337B2 (en) * 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10254304A1 (de) 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
US7202252B2 (en) 2003-02-19 2007-04-10 Endacea, Inc. A1 adenosine receptor antagonists
TW200500070A (en) 2003-04-25 2005-01-01 Novacardia Inc Method of improved diuresis in individuals with impaired renal function
RU2318825C2 (ru) * 2003-05-06 2008-03-10 Си Ви Терапьютикс, Инк. Производные ксантина в качестве антагонистов a2b аденозинового рецептора
US7247639B2 (en) * 2003-06-06 2007-07-24 Endacea, Inc. A1 adenosine receptor antagonists
JP2007506804A (ja) * 2003-06-09 2007-03-22 エンダセア， インコーポレイテッド Ａ１アデノシンレセプターアンタゴニスト
US7566707B2 (en) 2003-06-18 2009-07-28 Boehringer Ingelheim International Gmbh Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10355304A1 (de) 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004009039A1 (de) 2004-02-23 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
US7393847B2 (en) 2004-03-13 2008-07-01 Boehringer Ingleheim International Gmbh Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
US7179809B2 (en) * 2004-04-10 2007-02-20 Boehringer Ingelheim International Gmbh 2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
US7439370B2 (en) 2004-05-10 2008-10-21 Boehringer Ingelheim International Gmbh Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
DE102004030502A1 (de) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004043944A1 (de) 2004-09-11 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004044221A1 (de) 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
WO2006138376A1 (en) * 2005-06-16 2006-12-28 Cv Therapeutics, Inc. Prodrugs of a2b adenosine receptor antagonists
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CN103951667A (zh) * 2006-05-04 2014-07-30 勃林格殷格翰国际有限公司 多晶型
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
CA2660197A1 (en) * 2006-08-08 2008-02-14 Boehringer Ingelheim International Gmbh Pyrrolo[3,2-d]pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus
RU2344137C1 (ru) * 2007-07-18 2009-01-20 Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО БГМУ РОСЗДРАВА) Производные 8-амино-7-(2-гидроксипропил-1)-1,3-диметилксантина гидрохлорида, проявляющие гемореологическую активность
BRPI0815405A2 (pt) * 2007-08-17 2015-02-03 Boehringer Ingelheim Int Compostos derivados de purina, processo para a preparação de uma composição farmacêutica e uso dos mesmos
US9522916B2 (en) 2007-12-21 2016-12-20 Constance Neely Wilson A1 adenosine receptor antagonists
US7928259B2 (en) * 2008-02-12 2011-04-19 Frx Polymers, Inc. Diaryl alkylphosphonates and methods for preparing same
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
JP5906086B2 (ja) * 2008-08-15 2016-04-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｆａｂ関連疾患の治療に用いるためのプリン誘導体
CA2736421A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
JP5334511B2 (ja) * 2008-09-22 2013-11-06 日本精化株式会社 化粧料
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CA2745037C (en) 2008-12-23 2020-06-23 Boehringer Ingelheim International Gmbh Salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8(3-(r)-amino-piperidin-1-yl)-xanthine
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
EP2410855B1 (en) * 2009-03-26 2016-06-01 Mapi Pharma Limited Process for the preparation of alogliptin
EA034869B1 (ru) 2009-11-27 2020-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
US8518957B2 (en) 2009-12-02 2013-08-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methanocarba adenosine derivatives, pharmaceutical compositions, and method of reducing intraocular pressure
CN102946875A (zh) 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
ES2802243T3 (es) 2010-06-24 2021-01-18 Boehringer Ingelheim Int Terapia para la diabetes
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
MX366629B (es) 2011-07-15 2019-07-17 Boehringer Ingelheim Int Quinazolinas sustituidas, su preparación y su uso en composiciones farmacéuticas.
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
ES2929025T3 (es) 2012-05-14 2022-11-24 Boehringer Ingelheim Int Linagliptina, un derivado de xantina como inhibidor de dpp-4, para su uso en el tratamiento del SRIS y/o de la septicemia
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
AU2017276758A1 (en) 2016-06-10 2018-11-08 Boehringer Ingelheim International Gmbh Combinations of Linagliptin and metformin
RU2643336C1 (ru) * 2016-10-03 2018-01-31 Общество с Ограниченной Ответственностью "Компания "ЭЛТА" СРЕДСТВО, ПРОЯВЛЯЮЩЕЕ АНТИТРОМБОТИЧЕСКИЙ ЭФФЕКТ ПОСРЕДСТВОМ БЛОКИРОВАНИЯ РЕЦЕПТОРОВ ТРОМБОЦИТОВ ГП IIb-IIIa (ВАРИАНТЫ)
CN109796453A (zh) * 2019-02-12 2019-05-24 南京纽邦生物科技有限公司 一种1,7-二甲基黄嘌呤的制备方法
US20240002416A1 (en) 2020-10-15 2024-01-04 Rheinische-Friedrich-Wilhelms-Universität Bonn MRGPRX4 Agonists and Antagonists

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452788A (en) * 1982-04-21 1984-06-05 Warner-Lambert Company Substituted 8-phenylxanthines
FR2531085A1 (fr) * 1982-07-28 1984-02-03 Adir Nouveaux derives de la xanthine, leur procede de preparation et les compositions pharmaceutiques les renfermant
US4593095A (en) * 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
CS238038B1 (en) * 1983-10-07 1985-11-13 Antonin Holy Medical drug with antivirus effect
US4696932A (en) * 1984-10-26 1987-09-29 The United States Of America As Represented By The Department Of Health And Human Services Biologically-active xanthine derivatives
GB8510758D0 (en) * 1985-04-27 1985-06-05 Wellcome Found Compounds
US4772607A (en) * 1986-05-20 1988-09-20 Warner-Lambert Company Dialkenyl derivatives of xanthine, pharmaceutical compositions and methods of use therefor
US4783530A (en) * 1986-11-13 1988-11-08 Marion Laboratories, Inc. 8-arylxanthines
US4968672A (en) * 1987-01-02 1990-11-06 The United States Of America As Represented By The Department Of Health And Human Services Adenosine receptor prodrugs
US5032593A (en) * 1988-07-01 1991-07-16 Marion Merrell Dow Inc. Method of treating bronchoconstriction with 1,3-unsymmetrical straight chain alkyl-substituted 8-phenylxanthines
DE8817122U1 (de) * 1988-12-22 1993-02-04 Boehringer Ingelheim Kg, 55218 Ingelheim Neue Xanthinderivate mit Adenosinantogenistischer Wirkung
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
ES2130138T3 (es) * 1990-10-18 1999-07-01 Kyowa Hakko Kogyo Kk Derivado de xantina.
CA2061544A1 (en) * 1991-02-25 1992-08-26 Fumio Suzuki Xanthine compounds
TW252044B (cs) * 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
US5366977A (en) * 1992-09-29 1994-11-22 The United States Of America, As Represented By The Department Of Health And Human Services Method of treating cystic fibrosis using 8-cyclopentyl-1,3-dipropylxanthine or xanthine amino congeners

Also Published As

Publication number Publication date
SG55038A1 (en) 1998-12-21
NZ254804A (en) 1997-01-29
FI950542L (fi) 1995-02-08
SK18595A3 (en) 1995-07-11
RU95109100A (ru) 1996-12-27
MX9304819A (es) 1994-02-28
RU2138500C1 (ru) 1999-09-27
CA2140883A1 (en) 1994-02-17
FI950542A0 (fi) 1995-02-08
TW252044B (cs) 1995-07-21
CZ34895A3 (en) 1995-10-18
HU9302302D0 (en) 1993-10-28
CN1043348C (zh) 1999-05-12
FI950542A7 (fi) 1995-02-08
PL307397A1 (en) 1995-05-15
IL106624A (en) 1999-01-26
CN1086818A (zh) 1994-05-18
PL176389B1 (pl) 1999-05-31
UA46697C2 (uk) 2002-06-17
HUT65734A (en) 1994-07-28
AU4707193A (en) 1994-03-03
AU681348B2 (en) 1997-08-28
US5719279A (en) 1998-02-17
CZ286459B6 (en) 2000-04-12
KR950702988A (ko) 1995-08-23
EP0654033A1 (de) 1995-05-24
JPH08500344A (ja) 1996-01-16
WO1994003456A1 (de) 1994-02-17
IL106624A0 (en) 1993-12-08
BG99489A (bg) 1996-01-31

Similar Documents

Publication Publication Date Title
BG62618B1 (bg) Асиметрично заместени ксантини с аденозинантагонистичнисвойства, метод за тяхното получаване и междинни съединения затази цел, приложение на тези съединения като фармакологичнисредства, фармацевтични смеси, които ги съдържат, и метод затяхното получаване
DE60008372T2 (de) Pharmazeutisch aktive verbindungen
JP4685243B2 (ja) ピリミド［６，１−ａ］イソキノリン−４−オン誘導体
AU724549B2 (en) Indazole derivatives and their use as inhibitors of phosphodiesterase (PDE) type IV and the production of tumor necrosis factor (TNF)
IE851146L (en) Pyridazinones.
TW203049B (cs)
US3995039A (en) Pyrazolo [1,5-a] [1,3,5] triazines
US6187780B1 (en) Assymetrically substituted xanthine derivatives having adenosine A1 antagonistic activity
JP3020281B2 (ja) 新規なトリアゾロプリン類、その調製方法及び医薬組成物としての使用
NZ208107A (en) 6-aryl-3(2h)-pyridazinones and pharmaceutical compositions
JPH06199866A (ja) ジアゼピン誘導体
KR880001719B1 (ko) 1,4,9,10-테트라하이드로-피라졸로[4,3-e]-피리도[3,2-b][1,4]디아제핀-10-온의 제조 방법
DE19816857A1 (de) Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE4325254A1 (de) Unsymmetrisch substituierte Xanthine
US4228168A (en) Azepino [1,2,3-lm]-β-carboline compounds and pharmaceutical composition thereof
JP4567883B2 (ja) 新規イミダゾトリアゾロピリミジン、それらの調製方法及び医薬組成物としてのそれらの使用
JPS6322562A (ja) 強心性、ホスホジエステラ−ゼ画分１１１抑制性及び／又は腎血管拡張性を持った４−窒素置換イソキノリノ−ル化合物
EP0272226A2 (en) 8-Azaxanthines alkylaminoalkyl or heterocyclylalkyl-substituted on the triazole ring, the salts thereof which are physiologically acceptable, their pharmaceutical compositions having antibronchospastic acivity, and the process for preparing the same
DE69318869T2 (de) Pyrazolo(3,4-a)acridinderivate als Analgetika
IE48176B1 (en) Ergot peptide alkaloid derivatives,processes for their preparation and pharmaceutical compositions containing them
US4482547A (en) Substituted-1,3,4-benzotriazepines
CA2242097C (en) Imidazotriazolopyrimidines, process for preparing them and their use as pharmaceutical compositions
KR20000064893A (ko) 트리아졸로퓨린,이의제조방법및이를함유하는약제학적제제
SE450122B (sv) N-substituerade ergolin- och 9,10-didehydro-ergolin-8-karboxamid- och -8-aminometyl-derivat, deras framstellning och farmaceutiska kompositioner
JPS61257984A (ja) イミダゾイソキノリンカルボン酸誘導体